Literature DB >> 24817628

Regulation of SRC kinases by microRNA-3607 located in a frequently deleted locus in prostate cancer.

Sharanjot Saini1, Shahana Majid2, Varahram Shahryari2, Z Laura Tabatabai2, Sumit Arora2, Soichiro Yamamura2, Yuichiro Tanaka2, Rajvir Dahiya2, Guoren Deng2.   

Abstract

Genomic studies suggest that deletions at chromosome (chr) 5q region (particularly chr5q14-q23) are frequent in prostate cancer, implicating this region in prostate carcinogenesis. However, the genes within this region are largely unknown. Here, we report for the first time the widespread attenuation of miR-3607, an miRNA gene located at chr5q14 region, in prostate cancer. Expression analyses of miR-3607 in a clinical cohort of prostate cancer specimens showed that miR-3607 is significantly attenuated and low miR-3607 expression is correlated with tumor progression and poor survival outcome in prostate cancer. Our analyses suggest that miR-3607 expression may be a clinically significant parameter with an associated diagnostic potential. We examined the functional significance of miR-3607 in prostate cancer cell lines and found that miR-3607 overexpression led to significantly decreased proliferation, apoptosis induction, and decreased invasiveness. Furthermore, our results suggest that miR-3607 directly represses oncogenic SRC family kinases LYN and SRC in prostate cancer. In view of our results, we propose that miR-3607 plays a tumor-suppressive role in prostate cancer by regulating SRC kinases that in turn regulates prostate carcinogenesis. To our knowledge, this is the first report that: (i) identifies a novel role for miR-3607 located in a frequently deleted region of prostate cancer and (ii) defines novel miRNA-mediated regulation of SRC kinases in prostate cancer. Because SRC kinases play a central role in prostate cancer progression and metastasis and are attractive targets, this study has potential implications in the design of better therapeutic modalities for prostate cancer management. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24817628      PMCID: PMC4351861          DOI: 10.1158/1535-7163.MCT-14-0017

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  50 in total

1.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

Authors:  Louis J Lombardo; Francis Y Lee; Ping Chen; Derek Norris; Joel C Barrish; Kamelia Behnia; Stephen Castaneda; Lyndon A M Cornelius; Jagabandhu Das; Arthur M Doweyko; Craig Fairchild; John T Hunt; Ivan Inigo; Kathy Johnston; Amrita Kamath; David Kan; Herbert Klei; Punit Marathe; Suhong Pang; Russell Peterson; Sidney Pitt; Gary L Schieven; Robert J Schmidt; John Tokarski; Mei-Li Wen; John Wityak; Robert M Borzilleri
Journal:  J Med Chem       Date:  2004-12-30       Impact factor: 7.446

2.  A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells.

Authors:  R C Bates; N S Edwards; G F Burns; D E Fisher
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

3.  Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase.

Authors:  L F Lee; J Guan; Y Qiu; H J Kung
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

4.  Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling.

Authors:  M Sumitomo; R Shen; M Walburg; J Dai; Y Geng; D Navarro; G Boileau; C N Papandreou; F G Giancotti; B Knudsen; D M Nanus
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

Review 5.  Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.

Authors:  Robert D Loberg; Christopher J Logothetis; Evan T Keller; Kenneth J Pienta
Journal:  J Clin Oncol       Date:  2005-11-10       Impact factor: 44.544

Review 6.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

7.  Allelic imbalance and microsatellite instability in prostatic adenocarcinoma.

Authors:  J M Cunningham; A Shan; M J Wick; S K McDonnell; D J Schaid; D J Tester; J Qian; S Takahashi; R B Jenkins; D G Bostwick; S N Thibodeau
Journal:  Cancer Res       Date:  1996-10-01       Impact factor: 12.701

8.  SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.

Authors:  Oleg Tatarov; Thomas J Mitchell; Morag Seywright; Hing Y Leung; Valerie G Brunton; Joanne Edwards
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

10.  Transforming growth factor beta down-regulates Src family protein tyrosine kinase signaling pathways.

Authors:  A Atfi; E Drobetsky; M Boissonneault; A Chapdelaine; S Chevalier
Journal:  J Biol Chem       Date:  1994-12-02       Impact factor: 5.157

View more
  10 in total

Review 1.  Missing link between microRNA and prostate cancer.

Authors:  Balraj Singh Gill; Jimi Marin Alex; Sanjeev Kumar
Journal:  Tumour Biol       Date:  2016-01-28

2.  Integrated miRNA and mRNA expression profiling of tension force-induced bone formation in periodontal ligament cells.

Authors:  Maolin Chang; Heng Lin; Meng Luo; Jie Wang; Guangli Han
Journal:  In Vitro Cell Dev Biol Anim       Date:  2015-06-20       Impact factor: 2.416

3.  The importance of Src signaling in sarcoma.

Authors:  Quanchi Chen; Zifei Zhou; Liancheng Shan; Hui Zeng; Yingqi Hua; Zhengdong Cai
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

4.  miR-143 Induces the Apoptosis of Prostate Cancer LNCap Cells by Suppressing Bcl-2 Expression.

Authors:  Zhiwei Ma; Yizhao Luo; Mingxing Qiu
Journal:  Med Sci Monit       Date:  2017-01-21

5.  MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity.

Authors:  Yang Wang; Ning Shao; Xueying Mao; Minmin Zhu; Weifei Fan; Zhixiang Shen; Rong Xiao; Chuncai Wang; Wenping Bao; Xinyu Xu; Chun Yang; Jian Dong; Deshui Yu; Yan Wu; Caixia Zhu; Liting Wen; Xiaojie Lu; Yong-Jie Lu; Ninghan Feng
Journal:  Oncotarget       Date:  2016-07-26

6.  Dysregulation of miR-3607 predicts prognosis of hepatocellular carcinoma and regulates tumor cell proliferation, migration and invasion.

Authors:  Wenwen Dou; Min Yang; Yan Su; Ruizhu Xie
Journal:  Diagn Pathol       Date:  2020-05-13       Impact factor: 2.644

7.  Characterization of kinase gene expression and splicing profile in prostate cancer with RNA-Seq data.

Authors:  Huijuan Feng; Tingting Li; Xuegong Zhang
Journal:  BMC Genomics       Date:  2018-08-13       Impact factor: 3.969

8.  miR-3607-3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2.

Authors:  Peng Gao; Huan Wang; Jiarui Yu; Jie Zhang; Zhao Yang; Meiyue Liu; Yi Niu; Xiaomei Wei; Wei Wang; Hongmin Li; Yadi Wang; Guogui Sun
Journal:  PLoS Genet       Date:  2018-12-17       Impact factor: 5.917

9.  MicroRNA-1291 Is Associated With Locoregional Metastases in Patients With Early-Stage Breast Cancer.

Authors:  Daniel Escuin; Laura López-Vilaró; Olga Bell; Josefina Mora; Antonio Moral; José Ignacio Pérez; Cristina Arqueros; Teresa Ramón Y Cajal; Enrique Lerma; Agustí Barnadas
Journal:  Front Genet       Date:  2020-12-02       Impact factor: 4.599

10.  Using microRNAs as Novel Predictors of Urologic Cancer Survival: An Integrated Analysis.

Authors:  Zhicong Chen; Yonghao Zhan; Jieshan Chi; Shuyuan Guo; Xinliang Zhong; Anbang He; Jianrong Zheng; Yanqing Gong; Xuesong Li; Liqun Zhou
Journal:  EBioMedicine       Date:  2018-07-21       Impact factor: 8.143

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.